You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFurazolidone
Accession NumberDB00614  (APRD00988)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone binds bacterial DNA which leads to the gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)
Structure
Thumb
Synonyms
3-(5'-Nitrofurfuralamino)-2-oxazolidone
3-[(5-Nitrofurfurylidene)amino]-2-oxazolidinone
3-[(5-Nitrofurfurylidene)amino]-2-oxazolidone
3-[(5-Nitrofurylidene)amino]-2-oxazolidone
3-{[(5-nitro-2-furanyl)methylene]amino}-2-oxazolidinone
5-Nitro-N-(2-oxo-3-oxazolidinyl)-2-furanmethanimine
Furazolidona
Furazolidone
Furazolidonum
Furoxone
FZL
N-(5-Nitro-2-furfurylidene)-3-amino-2-oxazolidone
N-(5-Nitro-2-furfurylidene)-3-aminooxazolidine-2-one
Nitrofurazolidone
Nitrofurazolidonum
External Identifiers
  • USAF EA-1
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Dependal-MGlaxoSmithKline
FuroxoneRoberts Laboratories
Brand mixturesNot Available
SaltsNot Available
Categories
UNII5J9CPU3RE0
CAS number67-45-8
WeightAverage: 225.1583
Monoisotopic: 225.038570349
Chemical FormulaC8H7N3O5
InChI KeyPLHJDBGFXBMTGZ-WEVVVXLNSA-N
InChI
InChI=1S/C8H7N3O5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5H,3-4H2/b9-5+
IUPAC Name
3-{[(5-nitrofuran-2-yl)methylidene]amino}-1,3-oxazolidin-2-one
SMILES
[O-][N+](=O)C1=CC=C(O1)C=NN1CCOC1=O
Pharmacology
IndicationFor the specific and symptomatic treatment of bacterial or protozoal diarrhea and enteritis caused by susceptible organisms.
Structured Indications Not Available
PharmacodynamicsFuroxone has a broad antibacterial spectrum covering the majority of gastrointestinal tract pathogens including E. coli, staphylococci, Salmonella, Shigella, Proteus, Aerobacter aerogenes, Vibrio cholerae and Giardia lamblia. Its bactericidal activity is based upon its interference with DNA replication and protein production; this antimicrobial action minimizes the development of resistant organisms.
Mechanism of actionFurazolidone and its related free radical products are believed to bind DNA and induce cross-links. Bacterial DNA is particularly susceptible to this drug leading to high levels of mutations (transitions and transversions) in the bacterial chromosome.
TargetKindPharmacological actionActionsOrganismUniProt ID
DNANucleotideyes
cross-linking/alkylation
Humannot applicabledetails
Related Articles
AbsorptionRadiolabeled drug studies indicate that furazolidone is well absorbed following oral administration
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Furazolidone is rapidly and extensively metabolized; the primary metabolic pathway identified begins with nitro-reduction to the aminofuran derivative. Two major metabolites are produced: 3-amino-2-oxazolidone (AOZ) or beta-hydroxyethylhydrazine (HEH). AOZ is responsible for monoamine oxidase inhibition. Detoxification and elimination of the drug is done primarily by conjugation with glutathione.

SubstrateEnzymesProduct
Furazolidone
Not Available
beta-HydroxyethylhydrazineDetails
Furazolidone
Not Available
3-amino-2-oxazolidoneDetails
Route of eliminationNot Available
Half life10 minutes
ClearanceNot Available
ToxicityReactions to Furoxone have been reported including a fall in blood pressure, urticaria, fever, arthralgia, and a vesicular morbilliform rash. Other adverse effects can include a brown discoloration of the urine; hemolysis can occur in G6PDH-deficient patients. The drug has a monoamine oxidase (MAO) inhibitory effect and should never be given concurrently to individuals already taking MAO inhibitors.
Affected organisms
  • Microbes (bacteria, parasites)
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineFurazolidone may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineFurazolidone may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineFurazolidone may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineFurazolidone may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEFurazolidone may increase the hypertensive activities of 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AcarboseFurazolidone may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololFurazolidone may increase the hypotensive activities of Acebutolol.Approved
AlbiglutideFurazolidone may increase the hypoglycemic activities of Albiglutide.Approved
AlfentanilAlfentanil may increase the serotonergic activities of Furazolidone.Approved, Illicit
AliskirenFurazolidone may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Furazolidone.Approved, Investigational
AlogliptinFurazolidone may increase the hypoglycemic activities of Alogliptin.Approved
AlprenololFurazolidone may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Furazolidone.Approved
AmbrisentanFurazolidone may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmineptineFurazolidone may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmitriptylineFurazolidone may increase the serotonergic activities of Amitriptyline.Approved
AmlodipineFurazolidone may increase the hypotensive activities of Amlodipine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Amoxapine.Approved
AmphetamineFurazolidone may increase the hypertensive activities of Amphetamine.Approved, Illicit
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Furazolidone.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Arformoterol.Approved, Investigational
AtenololFurazolidone may increase the hypotensive activities of Atenolol.Approved
AtomoxetineFurazolidone may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineFurazolidone may increase the hypertensive activities of Atropine.Approved, Vet Approved
BambuterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Bambuterol.Approved
BenazeprilFurazolidone may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideFurazolidone may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinFurazolidone may increase the hypertensive activities of Benmoxin.Withdrawn
BenzphetamineFurazolidone may increase the hypertensive activities of Benzphetamine.Approved, Illicit
BepridilFurazolidone may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Furazolidone.Approved
BetaxololFurazolidone may increase the hypotensive activities of Betaxolol.Approved
BethanidineFurazolidone may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Furazolidone is combined with Bezafibrate.Approved
BimatoprostFurazolidone may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololFurazolidone may increase the hypotensive activities of Bisoprolol.Approved
BosentanFurazolidone may increase the hypotensive activities of Bosentan.Approved, Investigational
BretyliumFurazolidone may increase the hypotensive activities of Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Brimonidine.Approved
BrimonidineFurazolidone may increase the hypotensive activities of Brimonidine.Approved
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Furazolidone.Approved, Investigational
BupranololFurazolidone may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Furazolidone.Approved, Illicit, Investigational, Vet Approved
BupropionFurazolidone may increase the hypertensive activities of Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Furazolidone.Approved, Investigational
CabergolineThe metabolism of Cabergoline can be decreased when combined with Furazolidone.Approved
CanagliflozinFurazolidone may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanFurazolidone may increase the hypotensive activities of Candesartan.Approved
CandoxatrilFurazolidone may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilFurazolidone may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Furazolidone.Approved, Investigational
CaroxazoneFurazolidone may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololFurazolidone may increase the hypotensive activities of Carteolol.Approved
CarvedilolFurazolidone may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololFurazolidone may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideFurazolidone may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineFurazolidone may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorpropamideFurazolidone may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneFurazolidone may increase the hypotensive activities of Chlorthalidone.Approved
CilazaprilFurazolidone may increase the hypotensive activities of Cilazapril.Approved
CirazolineFurazolidone may increase the hypertensive activities of Cirazoline.Experimental
CitalopramFurazolidone may increase the serotonergic activities of Citalopram.Approved
ClemastineFurazolidone may increase the anticholinergic activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Clenbuterol.Approved, Vet Approved
ClomipramineFurazolidone may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
ClonidineFurazolidone may increase the hypotensive activities of Clonidine.Approved
CryptenamineFurazolidone may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Furazolidone.Approved
CyclothiazideFurazolidone may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineFurazolidone may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinFurazolidone may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetineFurazolidone may increase the serotonergic activities of Dapoxetine.Investigational
DebrisoquinFurazolidone may increase the hypotensive activities of Debrisoquin.Approved
DeserpidineFurazolidone may increase the hypotensive activities of Deserpidine.Approved
DesipramineFurazolidone may increase the serotonergic activities of Desipramine.Approved
DesvenlafaxineFurazolidone may increase the serotonergic activities of Desvenlafaxine.Approved
DexmethylphenidateFurazolidone may increase the hypertensive activities of Dexmethylphenidate.Approved
DextroamphetamineFurazolidone may increase the hypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanFurazolidone may increase the serotonergic activities of Dextromethorphan.Approved
DiazoxideFurazolidone may increase the hypotensive activities of Diazoxide.Approved
DiethylpropionFurazolidone may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazineFurazolidone may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Furazolidone.Approved
DiltiazemFurazolidone may increase the hypotensive activities of Diltiazem.Approved
DipivefrinThe risk or severity of adverse effects can be increased when Furazolidone is combined with Dipivefrin.Approved
DisopyramideFurazolidone may increase the hypoglycemic activities of Disopyramide.Approved
DobutamineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Dobutamine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamideFurazolidone may increase the hypotensive activities of Dorzolamide.Approved
DosulepinFurazolidone may increase the serotonergic activities of Dosulepin.Approved
DoxapramFurazolidone may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinFurazolidone may increase the hypotensive activities of Doxazosin.Approved
DoxepinFurazolidone may increase the serotonergic activities of Doxepin.Approved
DoxylamineFurazolidone may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DroxidopaThe risk or severity of adverse effects can be increased when Furazolidone is combined with Droxidopa.Approved, Investigational
DulaglutideFurazolidone may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineFurazolidone may increase the serotonergic activities of Duloxetine.Approved
EfonidipineFurazolidone may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Furazolidone.Approved, Investigational
EmpagliflozinFurazolidone may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilFurazolidone may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatFurazolidone may increase the hypotensive activities of Enalaprilat.Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Furazolidone.Approved, Investigational
EphedraThe risk or severity of adverse effects can be increased when Furazolidone is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineFurazolidone may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EpoprostenolFurazolidone may increase the hypotensive activities of Epoprostenol.Approved
EprosartanFurazolidone may increase the hypotensive activities of Eprosartan.Approved
ErgotamineFurazolidone may increase the hypertensive activities of Ergotamine.Approved
EscitalopramFurazolidone may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmirtazapineFurazolidone may increase the serotonergic activities of Esmirtazapine.Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Furazolidone.Approved
EtoperidoneFurazolidone may increase the serotonergic activities of Etoperidone.Approved
ExenatideFurazolidone may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipineFurazolidone may increase the hypotensive activities of Felodipine.Approved, Investigational
FenfluramineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Fenfluramine.Illicit, Withdrawn
FenoldopamFurazolidone may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Fenoterol.Approved
FentanylFentanyl may increase the serotonergic activities of Furazolidone.Approved, Illicit, Investigational, Vet Approved
FluoxetineFurazolidone may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FluvoxamineFurazolidone may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Formoterol.Approved, Investigational
FosinoprilFurazolidone may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Furazolidone.Approved, Investigational
GliclazideFurazolidone may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideFurazolidone may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideFurazolidone may increase the hypoglycemic activities of Glipizide.Approved
GlyburideFurazolidone may increase the hypoglycemic activities of Glyburide.Approved
GuanabenzFurazolidone may increase the hypotensive activities of Guanabenz.Approved
GuanadrelFurazolidone may increase the hypotensive activities of Guanadrel.Approved
GuanethidineFurazolidone may increase the hypotensive activities of Guanethidine.Approved
GuanfacineFurazolidone may increase the hypotensive activities of Guanfacine.Approved, Investigational
HexamethoniumFurazolidone may increase the hypotensive activities of Hexamethonium.Experimental
HydracarbazineFurazolidone may increase the hypertensive activities of Hydracarbazine.Approved
HydralazineFurazolidone may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideFurazolidone may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideFurazolidone may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Hydromorphone.Approved, Illicit
Hydroxyamphetamine hydrobromideFurazolidone may increase the hypertensive activities of Hydroxyamphetamine hydrobromide.Approved
ImidaprilFurazolidone may increase the hypotensive activities of Imidapril.Investigational
ImipramineFurazolidone may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Indacaterol.Approved
IndalpineFurazolidone may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideFurazolidone may increase the hypotensive activities of Indapamide.Approved
IndenololFurazolidone may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminFurazolidone may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartFurazolidone may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirFurazolidone may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineFurazolidone may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineFurazolidone may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanFurazolidone may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproFurazolidone may increase the hypoglycemic activities of Insulin Lispro.Approved
IproclozideFurazolidone may increase the hypertensive activities of Iproclozide.Withdrawn
IproniazidFurazolidone may increase the hypertensive activities of Iproniazid.Withdrawn
IrbesartanFurazolidone may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidFurazolidone may increase the hypertensive activities of Isocarboxazid.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Isoprenaline.Approved
IsradipineFurazolidone may increase the hypotensive activities of Isradipine.Approved
KetanserinFurazolidone may increase the hypotensive activities of Ketanserin.Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Furazolidone.Approved, Nutraceutical
LabetalolFurazolidone may increase the hypotensive activities of Labetalol.Approved
LacidipineFurazolidone may increase the hypotensive activities of Lacidipine.Approved
LanreotideFurazolidone may increase the hypoglycemic activities of Lanreotide.Approved
LatanoprostFurazolidone may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineFurazolidone may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Furazolidone.Approved
LevomilnacipranFurazolidone may increase the serotonergic activities of Levomilnacipran.Approved
LevonordefrinFurazolidone may increase the hypertensive activities of Levonordefrin.Approved
LinezolidThe risk or severity of adverse effects can be increased when Furazolidone is combined with Linezolid.Approved, Investigational
LiraglutideFurazolidone may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineFurazolidone may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilFurazolidone may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Furazolidone.Approved
LithiumThe risk or severity of adverse effects can be increased when Furazolidone is combined with Lithium.Approved
LofexidineFurazolidone may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanFurazolidone may increase the hypotensive activities of Losartan.Approved
Lu AA21004The metabolism of Lu AA21004 can be decreased when combined with Furazolidone.Investigational
MacitentanFurazolidone may increase the hypotensive activities of Macitentan.Approved
ManidipineFurazolidone may increase the hypotensive activities of Manidipine.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Furazolidone.Approved
MebanazineFurazolidone may increase the hypertensive activities of Mebanazine.Withdrawn
MecamylamineFurazolidone may increase the hypotensive activities of Mecamylamine.Approved
MecaserminFurazolidone may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MephedroneFurazolidone may increase the hypertensive activities of Mephedrone.Investigational
MephentermineFurazolidone may increase the hypertensive activities of Mephentermine.Approved
MequitazineFurazolidone may increase the anticholinergic activities of Mequitazine.Approved
MetaraminolFurazolidone may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminFurazolidone may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Methadone.Approved
MethamphetamineFurazolidone may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethoxamineFurazolidone may increase the hypertensive activities of Methoxamine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Furazolidone is combined with Methyldopa.Approved
Methylene blueFurazolidone may increase the serotonergic activities of Methylene blue.Investigational
MethylphenidateFurazolidone may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MetipranololFurazolidone may increase the hypotensive activities of Metipranolol.Approved
MetolazoneFurazolidone may increase the hypotensive activities of Metolazone.Approved
MetoprololFurazolidone may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineFurazolidone may increase the hypotensive activities of Metyrosine.Approved
MianserinFurazolidone may increase the neurotoxic activities of Mianserin.Approved
MibefradilFurazolidone may increase the hypotensive activities of Mibefradil.Withdrawn
MidodrineFurazolidone may increase the hypertensive activities of Midodrine.Approved
MifepristoneFurazolidone may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolFurazolidone may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranFurazolidone may increase the serotonergic activities of Milnacipran.Approved
MinaprineFurazolidone may increase the hypertensive activities of Minaprine.Approved
MinoxidilFurazolidone may increase the hypotensive activities of Minoxidil.Approved
MirtazapineFurazolidone may increase the central neurotoxic activities of Mirtazapine.Approved
MMDAFurazolidone may increase the hypertensive activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Furazolidone is combined with Moclobemide.Approved
MoexiprilFurazolidone may increase the hypotensive activities of Moexipril.Approved
MorphineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Morphine.Approved, Investigational
MoxonidineFurazolidone may increase the hypotensive activities of Moxonidine.Approved
NadololFurazolidone may increase the hypotensive activities of Nadolol.Approved
NaftopidilFurazolidone may increase the hypotensive activities of Naftopidil.Investigational
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Furazolidone.Approved, Investigational
NateglinideFurazolidone may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololFurazolidone may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneFurazolidone may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NialamideFurazolidone may increase the hypertensive activities of Nialamide.Withdrawn
NicardipineFurazolidone may increase the hypotensive activities of Nicardipine.Approved
NicorandilFurazolidone may increase the hypotensive activities of Nicorandil.Approved
NiguldipineFurazolidone may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineFurazolidone may increase the hypotensive activities of Nilvadipine.Approved
NimodipineFurazolidone may increase the hypotensive activities of Nimodipine.Approved
NisoldipineFurazolidone may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineFurazolidone may increase the hypotensive activities of Nitrendipine.Approved
NitroprussideFurazolidone may increase the hypotensive activities of Nitroprusside.Approved
NorepinephrineFurazolidone may increase the hypertensive activities of Norepinephrine.Approved
NortriptylineFurazolidone may increase the serotonergic activities of Nortriptyline.Approved
OctamoxinFurazolidone may increase the hypertensive activities of Octamoxin.Withdrawn
OctreotideFurazolidone may increase the hypoglycemic activities of Octreotide.Approved, Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Olanzapine.Approved, Investigational
OlmesartanFurazolidone may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Olodaterol.Approved
OmapatrilatFurazolidone may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolFurazolidone may increase the serotonergic activities of Opipramol.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Orciprenaline.Approved
OxprenololFurazolidone may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Furazolidone.Approved, Investigational, Vet Approved
PargylineFurazolidone may increase the hypertensive activities of Pargyline.Approved
ParoxetineFurazolidone may increase the serotonergic activities of Paroxetine.Approved, Investigational
PasireotideFurazolidone may increase the hypoglycemic activities of Pasireotide.Approved
PenbutololFurazolidone may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineFurazolidone may increase the hypoglycemic activities of Pentamidine.Approved
PentoliniumFurazolidone may increase the hypotensive activities of Pentolinium.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Furazolidone.Approved, Vet Approved, Withdrawn
PerindoprilFurazolidone may increase the hypotensive activities of Perindopril.Approved
PethidineFurazolidone may increase the serotonergic activities of Pethidine.Approved
PhenelzineFurazolidone may increase the hypertensive activities of Phenelzine.Approved
PheniprazineFurazolidone may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenoxybenzamineFurazolidone may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineFurazolidone may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhentermineFurazolidone may increase the hypertensive activities of Phentermine.Approved, Illicit
PhentolamineFurazolidone may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineFurazolidone may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Furazolidone.Approved, Illicit
PinacidilFurazolidone may increase the hypotensive activities of Pinacidil.Withdrawn
PindololFurazolidone may increase the hypotensive activities of Pindolol.Approved
PioglitazoneFurazolidone may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Pirbuterol.Approved
PirlindoleFurazolidone may increase the hypertensive activities of Pirlindole.Approved
PivhydrazineFurazolidone may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenFurazolidone may increase the anticholinergic activities of Pizotifen.Approved
PolythiazideFurazolidone may increase the hypotensive activities of Polythiazide.Approved
PramlintideFurazolidone may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinFurazolidone may increase the hypotensive activities of Prazosin.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Procaterol.Approved
PropranololFurazolidone may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineFurazolidone may increase the serotonergic activities of Protriptyline.Approved
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Furazolidone.Investigational
PseudoephedrineFurazolidone may increase the hypertensive activities of Pseudoephedrine.Approved
QuinaprilFurazolidone may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineFurazolidone may increase the hypoglycemic activities of Quinine.Approved
RamiprilFurazolidone may increase the hypotensive activities of Ramipril.Approved
RasagilineFurazolidone may increase the hypertensive activities of Rasagiline.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Furazolidone.Approved
RemikirenFurazolidone may increase the hypotensive activities of Remikiren.Approved
RepaglinideFurazolidone may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineFurazolidone may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Reserpine.Approved
RilmenidineFurazolidone may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatFurazolidone may increase the hypotensive activities of Riociguat.Approved
RitobegronFurazolidone may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Ritodrine.Approved
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Furazolidone.Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Furazolidone.Approved, Investigational
RosiglitazoneFurazolidone may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SafrazineFurazolidone may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Salmeterol.Approved
SaprisartanFurazolidone may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinFurazolidone may increase the hypoglycemic activities of Saxagliptin.Approved
SelegilineFurazolidone may increase the hypertensive activities of Selegiline.Approved, Investigational, Vet Approved
SelexipagFurazolidone may increase the hypotensive activities of Selexipag.Approved
SertralineFurazolidone may increase the serotonergic activities of Sertraline.Approved
SitagliptinFurazolidone may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanFurazolidone may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilFurazolidone may increase the hypotensive activities of Spirapril.Approved
SufentanilSufentanil may increase the serotonergic activities of Furazolidone.Approved, Investigational
SulfadiazineFurazolidone may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleFurazolidone may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleFurazolidone may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Furazolidone.Approved, Investigational
SunitinibFurazolidone may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Furazolidone.Approved
TelmisartanFurazolidone may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilFurazolidone may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Terbutaline.Approved
TerlipressinFurazolidone may increase the hypotensive activities of Terlipressin.Approved, Investigational
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Furazolidone.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Furazolidone.Approved
TetryzolineFurazolidone may increase the hypertensive activities of Tetryzoline.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Furazolidone.Approved
TiboloneFurazolidone may increase the hypotensive activities of Tibolone.Approved
TicrynafenFurazolidone may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololFurazolidone may increase the hypotensive activities of Timolol.Approved
TolazamideFurazolidone may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineFurazolidone may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideFurazolidone may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Furazolidone.Approved, Withdrawn
ToloxatoneFurazolidone may increase the hypertensive activities of Toloxatone.Approved
TorasemideFurazolidone may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Furazolidone.Approved, Investigational
TrandolaprilFurazolidone may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineFurazolidone may increase the hypertensive activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineFurazolidone may increase the hypertensive activities of Tranylcypromine.Approved
TravoprostFurazolidone may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Trazodone.Approved, Investigational
TreprostinilFurazolidone may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazideFurazolidone may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinFurazolidone may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanFurazolidone may increase the hypotensive activities of Trimethaphan.Approved
TrimipramineFurazolidone may increase the serotonergic activities of Trimipramine.Approved
UnoprostoneFurazolidone may increase the hypotensive activities of Unoprostone.Approved
ValsartanFurazolidone may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineFurazolidone may increase the serotonergic activities of Venlafaxine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Furazolidone.Approved
VinpocetineFurazolidone may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Furazolidone.Approved
XylometazolineFurazolidone may increase the hypotensive activities of Xylometazoline.Approved
ZimelidineFurazolidone may increase the serotonergic activities of Zimelidine.Withdrawn
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Furazolidone.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Drake, G.D., Gever, G. and Hayes, K.J.; U.S. Patent 2,759,931; August 21, 1956; assigned to The Norwich Pharmacal Company.
Gever, G. and O’Keefe, C.J.; U.S. Patent 2,927,l IO; March 1, 1960; assigned to The Norwich Pharmacal Company.

US2742462
General ReferencesNot Available
External Links
ATC CodesG01AX06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9038
Blood Brain Barrier+0.9117
Caco-2 permeable-0.5736
P-glycoprotein substrateNon-substrate0.7829
P-glycoprotein inhibitor INon-inhibitor0.7761
P-glycoprotein inhibitor IINon-inhibitor0.9597
Renal organic cation transporterNon-inhibitor0.8351
CYP450 2C9 substrateNon-substrate0.8117
CYP450 2D6 substrateNon-substrate0.8415
CYP450 3A4 substrateSubstrate0.5984
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9134
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.928
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8828
Ames testAMES toxic0.9108
CarcinogenicityNon-carcinogens0.9097
BiodegradationReady biodegradable0.8978
Rat acute toxicity2.1639 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7889
hERG inhibition (predictor II)Non-inhibitor0.9057
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Shire development inc
Packagers
  • Professional Co.
Dosage formsNot Available
Prices
Unit descriptionCostUnit
Furazolidone powder2.04USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point254-256Drake, G.D., Gever, G. and Hayes, K.J.; U.S. Patent 2,759,931; August 21, 1956; assigned to The Norwich Pharmacal Company. Gever, G. and O'Keefe, C.J.; U.S. Patent 2,927,l IO; March 1, 1960; assigned to The Norwich Pharmacal Company
water solubility40 mg/L (at 25 °C)MERCK INDEX (1996); pH 6
logP-0.04DEBNATH,AK ET AL. (1991)
Predicted Properties
PropertyValueSource
Water Solubility0.364 mg/mLALOGPS
logP0.15ALOGPS
logP0.87ChemAxon
logS-2.8ALOGPS
pKa (Strongest Basic)-2.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area100.86 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity51.09 m3·mol-1ChemAxon
Polarizability19.74 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as nitrofurans. These are compounds containing a furan ring which bears a nitro group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassFurans
Sub ClassNitrofurans
Direct ParentNitrofurans
Alternative Parents
Substituents
  • 2-nitrofuran
  • Oxazolidinone
  • Heteroaromatic compound
  • Organic nitro compound
  • Organic nitrite
  • C-nitro compound
  • Oxacycle
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic oxoazanium
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Organic cation
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
cross-linking/alkylation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Meng J, Mangat SS, Grudzinski IP, Law FC: Evidence of 14C-furazolidone metabolite binding to the hepatic DNA of trout. Drug Metabol Drug Interact. 1998;14(4):209-19. [PubMed:10694929 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
References
  1. Timperio AM, Kuiper HA, Zolla L: Identification of a furazolidone metabolite responsible for the inhibition of amino oxidases. Xenobiotica. 2003 Feb;33(2):153-67. [PubMed:12623758 ]
  2. Ali BH: Pharmacological, therapeutic and toxicological properties of furazolidone: some recent research. Vet Res Commun. 1999 Oct;23(6):343-60. [PubMed:10543364 ]
  3. Hoogenboom LA, Tomassini O, Oorsprong MB, Kuiper HA: Use of pig hepatocytes to study the inhibition of monoamine oxidase by furazolidone. Food Chem Toxicol. 1991 Mar;29(3):185-91. [PubMed:2032659 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Timperio AM, Kuiper HA, Zolla L: Identification of a furazolidone metabolite responsible for the inhibition of amino oxidases. Xenobiotica. 2003 Feb;33(2):153-67. [PubMed:12623758 ]
  2. Ali BH: Pharmacological, therapeutic and toxicological properties of furazolidone: some recent research. Vet Res Commun. 1999 Oct;23(6):343-60. [PubMed:10543364 ]
  3. Hoogenboom LA, Tomassini O, Oorsprong MB, Kuiper HA: Use of pig hepatocytes to study the inhibition of monoamine oxidase by furazolidone. Food Chem Toxicol. 1991 Mar;29(3):185-91. [PubMed:2032659 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23